BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the Senior Biotech Analysts at JPMorgan. And we're continuing the 2021 Healthcare Conference today with BioCryst. This year instead of going across the hall to the breakout room, you can use that blue, ask a question button to submit questions to the portal. They'll pop up for me, and I can ask management those questions during our Q&A session after the presentation.
But with that out of the way, let me turn it over to BioCryst's CEO, Jon Stonehouse.
Thanks, Jess, and thanks for inviting us to this year's JPMorgan Healthcare Conference. I'm about to make some forward-looking statements, and I want to remind you that those have risks associated with them, and you can find our risk factors listed on our website.
What I'm about to tell you is a story about a small company with a big dream, and this dream recently became a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |